Which hedge funds own AMLX? AMYLYX PHARMACEUTICALS INC, Q2 2026 13F holders
55 tracked hedge funds disclosed a position in AMLX (AMYLYX PHARMACEUTICALS INC) in their Q2 2026 13F filings, worth $689.8m in total. The largest holder by portfolio weight is Saturn V Capital Management LP at 11.9% of its book. 18 opened a new position this quarter: Ikarian Capital, LLC, Fox Run Management, L.L.C., Affinity Asset Advisors, LLC, Lighthouse Investment Partners, LLC. 5 exited: ACT Capital Management, LLC, Landscape Capital Management, L.L.C., Squarepoint Ops LLC.
- 55
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 18
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 5
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $39.6m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $3.6m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $690m
- Combined value Sum of the holders' reported positions in the security.
- 4.4%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| ACT Capital Management, LLC | 0.10% | $125k |
| Landscape Capital Management, L.L.C. | 0.01% | $170k |
| Squarepoint Ops LLC | 0.0% | $1.6m |
| Point72 Asset Management, L.P. | 0.0% | $1.5m |
| Verition Fund Management LLC | 0.0% | $184k |
Ownership over time
Who discovered AMLX first? Beta
The run: Q3 2024 → Q3 2026, +798%
| Almitas Capital LLC high conviction | Q2 2024 | 2.3% | +9.3 pts |
| Ikarian Capital, LLC | Q4 2023 | 0.3% | −2.0 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.